Articles published by Genmab

Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

June 27, 2023

From Genmab

Via Business Wire

Tickers GMAB

Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’

June 22, 2023

From Genmab

Via Business Wire

Tickers GMAB

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

June 09, 2023

From Genmab

Via Business Wire

Tickers GMAB

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

April 17, 2023

From Genmab

Via Business Wire

Tickers GMAB

Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

November 21, 2022

From Genmab

Via Business Wire

Tickers GMAB

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

June 11, 2022

From Genmab

Via Business Wire

Tickers GMAB

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022

From Genmab

Via Business Wire

Tickers GMAB

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

May 12, 2022

From Genmab

Via Business Wire

Tickers GMAB

Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

October 01, 2021

From Genmab

Via Business Wire

Tickers GMAB

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.